Topic

Articles

The Digital Medicine Society (DiMe) CEO Jennifer Goldsack and Takeda’s Head of Digital Health Sciences, Data Sciences Institute Shoibal Datta describe the current landscape of digitized clinical trials and the decisions needed to fully utilize their potential.

How Clinical Trials Can Thrive in the Digital Era

Webcasts

Webinar Date/Time: Wed, Nov 30, 2022 10:00 AM EST


De-risking DCTs with Quality Systems

Anticipating the need for both virtual and traditional sites during the planning process can provide high ROI for sponsors.

Is There a Positive Return on Investment on a Virtual Site?

Webinar Date/Time: Wednesday, December 7th, 2022 at 11am EST | 8am PST | 4pm GMT | 5pm CET

The Importance of IRT in the Decentralized Clinical Trial Landscape

Lead, Emerging Technology Strategy – Clinical Design, Delivery & Analytics, Eli Lilly and Company

Arthur Combs, MD is a clinician, serial entrepreneur and thought leader in wearable technology and digital biomarkers. He serves as a consultant to numerous companies especially those bringing new noninvasive or digital technology to market.

What is next for DCTs after acceleration from COVID-19? 

How Remote Patient Monitoring Technology Can Impact Decentralized Clinical Trials

Fan Gao, PhD, MS, is part of the ZS R&D excellence leadership team. She leads the digital and DCT vertical in clinical development.

Arnab Roy is a leader in ZS’s R&D excellence practice area and leads the development and global commercialization of ZS's DCT strategy and analytics solutions.

Ankur Vasudeva is a leader in ZS’s R&D excellence practice area and leads strategy and analytics work in the areas of DCT and clinical feasibility.

William Chaplin is a consultant for ZS's R&D excellence team and member of the digital and DCT vertical in clinical development.

Sites not expected to fade away even as DCTs continue to grow past COVID-19.

Adapting Site Selection for Clinical Trial Decentralization and the Future Landscape

Jonathan Rowe, PhD, MS, MA, has worked in the pharmaceutical industry across clinical, quality and corporate teams for over 25 years. He currently leads ZS’s clinical development quality, operations and risk management functions from the New York office.

works within ZS’s clinical development quality, operations and risk management practice, and is a consultant at the Princeton, New Jersey, office.

works within ZS’s digital and DCT vertical in clinical development and medical affairs practices, and is an associate consultant at the Evanston, Illinois, office.

Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.

Survey Results: GCP Quality and Risks in Decentralized Clinical Trials 

Tufts CSDD study in collaboration with ten biopharmaceutical organizations and CROs examines sponsor/CRO relationships.

The Impact of Decentralized and Hybrid Trials on Sponsor and CRO Collaborations

Ken Getz, executive director and research professor at the Tufts Center for the Study of Drug Development, discusses the value of breakthrough findings with ROI and eNPV models. 

New Data Reveals DCTs Yield Better Clinical Trial ROI

Vice President, Vault CDMS, Veeva Systems

Richard Young previously explained on ACT why sponsors need a strong data foundation for successful digital clinical trials. Now he focuses on how to address some of the associated data management challenges.

Trial Design